Aurinia Pharmaceuticals Operating Expenses Growth & History (AUPH)
Aurinia Pharmaceuticals's operating expenses was $178.1M for fiscal 2025.
View full Aurinia Pharmaceuticals company overviewAurinia Pharmaceuticals annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $178.1M | −$61.7M | −25.72% |
| 2024 | 2024-12-31 | $239.8M | −$27.4M | −10.25% |
| 2023 | 2023-12-31 | $267.2M | $21.7M | +8.84% |
| 2022 | 2022-12-31 | $245.5M | $19.2M | +8.47% |
| 2021 | 2021-12-31 | $226.3M | $71.9M | +46.59% |
| 2020 | 2020-12-31 | $154.4M | $63.1M | +69.19% |
| 2019 | 2019-12-31 | $91.3M | $35.6M | +63.83% |
| 2018 | 2018-12-31 | $55.7M | $8.4M | +17.80% |
| 2017 | 2017-12-31 | $47.3M | $22.1M | +87.64% |
| 2016 | 2016-12-31 | $25.2M | — | — |
Aurinia Pharmaceuticals quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $36.9M | −$13.0M | −26.13% |
| Q1 2026 | 2026-03-31 | $36.3M | −$4.3M | −10.67% |
| Q4 2025 | 2025-12-31 | $43.9M | −$17.7M | −28.70% |
| Q3 2025 | 2025-09-30 | $43.7M | −$12.3M | −21.96% |
| Q2 2025 | 2025-06-30 | $49.9M | −$8.8M | −14.96% |
| Q1 2025 | 2025-03-31 | $40.6M | −$22.9M | −36.09% |
| Q4 2024 | 2024-12-31 | $61.5M | −$13.2M | −17.70% |
| Q3 2024 | 2024-09-30 | $56.0M | −$14.8M | −20.85% |
| Q2 2024 | 2024-06-30 | $58.7M | $1.0M | +1.81% |
| Q1 2024 | 2024-03-31 | $63.6M | −$437,000 | −0.68% |
| Q4 2023 | 2023-12-31 | $74.8M | $18.2M | +32.25% |
| Q3 2023 | 2023-09-30 | $70.8M | $5.5M | +8.43% |
| Q2 2023 | 2023-06-30 | $57.7M | −$6.5M | −10.15% |
| Q1 2023 | 2023-03-31 | $64.0M | $4.5M | +7.54% |
| Q4 2022 | 2022-12-31 | $56.5M | $426,000 | +0.76% |
| Q3 2022 | 2022-09-30 | $65.3M | $258,000 | +0.40% |
| Q2 2022 | 2022-06-30 | $64.2M | $10.4M | +19.40% |
| Q1 2022 | 2022-03-31 | $59.5M | $8.1M | +15.64% |
| Q4 2021 | 2021-12-31 | $56.1M | −$2.0M | −3.40% |
| Q3 2021 | 2021-09-30 | $65.0M | $22.7M | +53.55% |
| Q2 2021 | 2021-06-30 | $53.8M | $26.9M | +99.89% |
| Q1 2021 | 2021-03-31 | $51.5M | $24.4M | +89.95% |
| Q4 2020 | 2020-12-31 | $58.1M | $23.2M | +66.57% |
| Q3 2020 | 2020-09-30 | $42.3M | $18.0M | +74.27% |
| Q2 2020 | 2020-06-30 | $26.9M | $9.7M | +56.60% |
| Q1 2020 | 2020-03-31 | $27.1M | $12.2M | +81.56% |
| Q4 2019 | 2019-12-31 | $34.9M | — | — |
| Q3 2019 | 2019-09-30 | $24.3M | — | — |
| Q2 2019 | 2019-06-30 | $17.2M | — | — |
| Q1 2019 | 2019-03-31 | $14.9M | — | — |
Aurinia Pharmaceuticals operating expenses trends
Over the last five fiscal years, Aurinia Pharmaceuticals's operating expenses increased from $154.4M to $178.1M, a change of $23.7M. The latest reported quarter, Q2 2026, shows $36.9M.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aurinia Pharmaceuticals source filings ↗